

Joris Vandeputte

President, IABS



Joris Vandeputte was elected President of IABS (International Alliance for Biological Standardization) in June 2016. He is founding member of IABS-EU the European affiliate of IABS. IABS-EU implements the objectives of IABS at European level. IABS-EU is partner of the EU IMI (Innovative Medicines Initiative) projects ZAPI and VAC2VAC (www.IMI.eu, www.zapi-imi.eu, www.vac2vac.eu)

IABS hold its founding congress in Lyon in 1955. It is the global independent platform, interface, where stake-holders meet for exchange of science and issues related to vaccines, cell and gene therapy and human Biotherapeutics. IABS stimulates consensus building which might eventually be translated in regulatory frameworks and advises to decision makers.

Joris Vandeputte is also founder and president of TRIVAROP, a public affairs consultancy advising companies and associations in the area of global health-care. Joris has more than 30 years industry and international organisation's experience in vaccines, conceiving and developing vaccine policies at global level and towards developing countries in particular. Working with European institutions and policy-makers on innovation, health and development is his main activity.

As a virologist at Ghent University (1976-1980), Joris discovered H1N1 flu as a pathogen for swine leading to a better understanding of H1N1 as a zoonosis. After his assignment as Veterinary Officer to control animal diseases in Belgium and the EU, Joris joined Institut Mérieux animal health which became Rhône Mérieux and later on Merial, where he occupied leading positions in global vaccine development, strategy, regulatory affairs, marketing and production, for animal vaccines and flu vaccines. In 2001 he joined The Vaccine Fund, where he coordinated relations with European institutions which led to substantial funding by the EU and European governments to GAVI. At Tuberculosis Vaccine Initiative (TBVI) in Lelystad, the Netherlands, Joris developed, with EU institutions, a financial and strategic framework about funding translation of innovation into vaccines for tuberculosis which would be accessible to global markets.

Joris is consultant for international organisations with particular emphasis on zoonoses, one Health approaches and health in developing countries.